U.S. Physical Therapy Reports Third Quarter 2023 Results
USPH Reports Record-High Third Quarter Patient Volume, Net Revenue Increases by 7.5%, Operating Costs Increase by 8.2%
Positive
The company reported a record-high third-quarter patient volume, with net patient revenue from physical therapy operations increasing by 9.0% to $127.2 million for the 2023 Third Quarter from $116.7 million for the 2022 Third Quarter.
Adjusted EBITDA increased by $1.6 million to $18.6 million for the 2023 Third Quarter from $17.0 million for the 2022 Third Quarter.
Net income attributable to USPH’s shareholders decreased to $9.3 million for the 2023 Third Quarter compared to $9.6 million for the 2022 Third Quarter.
The company's physical therapy gross profit increased by 5.4% in the 2023 Third Quarter as compared to the 2022 Third Quarter and has increased by 10.9% for the nine months ended September 30, 2023, versus the nine months ended September 30, 2022.
Negative
The net rate per patient visit decreased to $102.37 in the 2023 Third Quarter compared to $104.01 in the 2022 Third Quarter.
Earnings per share decreased to $0.51 for the 2023 Third Quarter compared to $0.72 for the 2022 Third Quarter.
IIP services revenue was $19.5 million for the 2023 Third Quarter compared to $20.2 million in the 2022 Third Quarter.
11/07/2023 - 04:30 PM
Reports Record-High Third Quarter Patient Volume
HOUSTON --(BUSINESS WIRE)--
U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the three and nine months ended September 30, 2023.
THIRD QUARTER FINANCIAL HIGHLIGHTS
Adjusted EBITDA, a non-Generally Accepted Accounting Principles (“GAAP”) measure, was $18.6 million $1.6 million $17.0 million
Net income attributable to USPH’s shareholders, a GAAP measure, was $9.3 million $9.6 million $0.51 $0.72
Operating Results per share, a non-GAAP measure, were $0.62 $0.58
Net patient revenue from physical therapy operations increased 9.0% to $127.2 million $116.7 million
Average visits per clinic per day was 29.7 in the 2023 Third Quarter, a record-high for a third quarter in the Company’s history, compared to 28.8 average visits per clinic per day in the 2022 Third Quarter. Total patient visits increased 10.8% in the 2023 Third Quarter as compared to the 2022 Third Quarter, with patient visits at mature clinics up 1.3% .
Net rate per patient visit was $102.37 $104.01 $102.03
Physical therapy total operating costs per patient visit were $84.49 0.8% from $85.14 $60.35 1.0% from $60.99
The Company’s physical therapy gross profit increased 5.4% in the 2023 Third Quarter as compared to the 2022 Third Quarter and has increased 10.9% for the nine months ended September 30, 2023, versus the nine months ended September 30, 2022.
Industrial injury prevention (“IIP”) services revenue was $19.5 million $20.2 million 22.7% in the 2023 Third Quarter from 21.9% in the 2022 Third Quarter.
During the 2023 Third Quarter, the Company added 19 clinics, including the acquisitions described below, and closed three clinics, bringing its total clinic count to 672 as of September 30, 2023, as compared to 614 clinics as of September 30, 2022.
On July 31, 2023, the Company acquired a 70% equity interest in a five-clinic practice for a purchase price of $2.1 million 30% equity interest. The business currently generates approximately $2.4 million
On September 29, 2023, the Company acquired 70% equity interests in two physical therapy practices with the current practice owners retaining 30% equity interests for a combined purchase price of $13.9 million $7.2 million
On October 31, 2023, the Company, through one of its IIP subsidiaries, acquired an IIP services and ergonomics software business for approximately $4.0 million 55% of the ergonomics software business. The combined businesses currently generate approximately $2.6 million
On November 6, 2023, the Company’s Board of Directors declared a quarterly dividend of $0.43
Management currently expects the Company’s Adjusted EBITDA for 2023 to be within its provided guidance range of $75.0 million $80.0 million “2023 Earnings Guidance” below for more information.
MANAGEMENT’S COMMENTS
Chris Reading, Chief Executive Officer, said, “Our team continues to produce excellent results despite the pressure from Medicare rate reductions, inflationary impacts, and an improving but still challenging hiring environment. Our clinic volumes were once again at record levels in the third quarter and our total operating costs per visit continued to trend below last year. We also added 19 clinics from acquisitions and de novos during the quarter, and purchased an IIP services and ergonomics software business subsequent to quarter-end that provides us an opportunity to expand the reach of our ergonomics program. We achieved rate increases in all payor categories other than Medicare in the third quarter and will continue to focus on this initiative to drive greater progress in our net rate as we go forward.”
Carey Hendrickson, Chief Financial Officer, said, “Our balance sheet is in an outstanding position with $149 million $120 million
2023 THIRD QUARTER VERSUS 2022 THIRD QUARTER
Total net revenue for the 2023 Third Quarter was $150.0 million 7.5% , compared to $139.6 million
Three Months Ended September 30,
Variance
2023
2022
$
%
Revenue related to:
(in thousands, except percentages)
Mature Clinics (1)
$
111,943
$
111,598
$
345
0.3
%
2023 clinic additions
3,598
-
3,598
*
(2)
2022 clinic additions
11,674
3,899
7,775
*
(2)
Clinics sold or closed (3)
28
1,213
(1,185
)
*
(2)
Net patient revenue from physical therapy operations
127,243
116,710
10,533
9.0
%
Other revenue
889
753
136
18.1
%
Physical therapy operations
128,132
117,463
10,669
9.1
%
Industrial injury prevention services
19,486
20,155
(669
)
(3.3
)%
Management contracts
2,389
1,984
405
20.4
%
$
150,007
$
139,602
$
10,405
7.5
%
___________________________
(1)
See Glossary of Terms – Revenue Metrics for the definition.
(2)
Not meaningful.
(3)
Revenue from closed clinics includes revenue from the eight and 16 clinics closed during the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively.
Revenue from physical therapy operations increased $10.7 million 9.1% , to $128.1 million $117.5 million 10.8% to 1,242,954 for the 2023 Third Quarter from 1,122,070 in the 2022 Third Quarter, with visits at mature clinics up 1.3% over the same periods.
Net rate per patient visit was $102.37 $104.01 $102.03
IIP services revenue decreased $0.7 million 3.3% , to $19.5 million $20.2 million
Operating costs were $122.1 million 81.4% of net revenue, compared to $112.8 million 80.8% of net revenue, for the 2022 Third Quarter. Total physical therapy costs per visit were $84.49 0.8% from $85.14 59.9% of net revenue for the 2023 Third Quarter versus 58.6% for the 2022 Third Quarter. On a cost per patient visit basis, physical therapy salaries and related costs per visit were $60.35 1.0% from $60.99 20.5% for the 2023 Third Quarter versus 21.3% for the 2022 Third Quarter. The provision for credit losses, as a percentage of total revenue, was 1.0% for both the 2023 Third Quarter and the 2022 Third Quarter. The following table provides a breakdown of operating costs.
Three Months Ended September 30,
Variance
2023
2022
$
%
Operating costs related to:
(In thousands, except percentages)
Mature Clinics (1)
$
91,822
$
90,811
$
1,011
1.1
%
2023 Clinic additions
3,395
-
3,395
*
(2)
2022 Clinic additions
9,665
3,482
6,183
*
(2)
Clinics sold or closed (3)
137
1,238
(1,101
)
*
(2)
Physical therapy operations
105,019
95,531
9,488
9.9
%
Industrial injury prevention services
15,062
15,750
(688
)
(4.4
)%
Management contracts
1,997
1,537
460
29.9
%
$
122,078
$
112,818
$
9,260
8.2
%
___________________________
(1)
See Glossary of Terms – Revenue Metrics for the definition.
(2)
Not meaningful.
(3)
Operating costs from closed clinics include costs from the eight and 16 clinics closed or sold during the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively.
Operating costs from physical therapy operations increased $9.5 million 9.9% , to $105.0 million $95.5 million
Operating costs from IIP services were down $0.7 million 4.4% , versus the comparable prior year period.
Gross profit for the 2023 Third Quarter increased $1.1 million 4.3% , to $27.9 million $26.8 million 18.6% in the 2023 Third Quarter from 19.2% in the 2022 Third Quarter. The following table provides a detailed breakdown of gross profit and related gross profit margins.
Three Months Ended September 30,
2023
2022
Variance
$
Margin %
$
Margin %
$
%
(In thousands, except percentages)
Physical therapy operations
$
23,113
18.0
%
$
21,932
18.7
%
$
1,181
5.4
%
Industrial injury prevention services
4,424
22.7
%
4,405
21.9
%
19
0.4
%
Management contracts
392
16.4
%
447
22.5
%
(55
)
(12.3
)%
Gross profit
$
27,929
18.6
%
$
26,784
19.2
%
$
1,145
4.3
%
Corporate office costs were $12.0 million 8.0% of net revenue, for the 2023 Third Quarter compared to $11.9 million 8.5% of net revenue, for the 2022 Third Quarter.
Operating income for the 2023 Third Quarter was $15.9 million 10.6% of net revenue, and $14.9 million 10.7% of net revenue, for the 2022 Third Quarter.
Total other (expense) income, net, was ($0.1) million in the 2023 Third Quarter compared to $1.1 million
Interest expense, net of $0.9 million “Balance Sheet and Cash Flow” section below, was $2.1 million $2.0 million 4.9% for the 2023 Third Quarter, with an all-in effective interest rate, including all associated costs, of 5.6% .
Interest income from investing excess cash (proceeds from the secondary offering sale of the Company’s stock completed in May 2023) in a high-yield savings account was $1.7 million
The Company revalued the contingent earn-out consideration related to acquisitions and recognized $0.2 million $2.0 million
The revaluation of a put-right liability resulted in $0.1 million $0.8 million
The provision for income taxes was $3.6 million $3.2 million 27.8% for the 2023 Third Quarter and 25.2% for the 2022 Third Quarter. A computation of our effective income tax rate is as follows:
Three Months Ended September 30,
2023
2022
(In thousands, except percentages)
Income before taxes
$
15,779
$
16,036
Less: Net income attributable to non-controlling interest:
Redeemable non-controlling interest - temporary equity
(1,976
)
(2,037
)
Non-controlling interest - permanent equity
(992
)
(1,227
)
(2,968
)
(3,264
)
Income before taxes less net income attributable to non-controlling interest
12,811
12,772
Provision for income taxes
$
3,557
$
3,215
Effective income tax rate
27.8
%
25.2
%
Net income attributable to non-controlling interest (temporary and permanent) was $3.0 million $3.3 million
Adjusted EBITDA, a non-GAAP measure, increased $1.6 million $18.6 million $17.0 million $1.7 million $9.2 million $0.62 $7.5 million $0.58
NINE MONTHS ENDED SEPTEMBER 30, 2023 VERSUS NINE MONTHS ENDED SEPTEMBER 30, 2022
Total net revenue for nine months ended September 30, 2023 (“2023 Nine Months”) was $450.0 million 9.2% , compared to $412.0 million
Nine Months Ended September 30,
Variance
2023
2022
$
%
Revenue related to:
(in thousands, except percentages)
Mature Clinics (1)
$
340,830
$
332,629
$
8,201
2.5
%
2023 clinic additions
5,888
-
5,888
*
(2)
2022 clinic additions
35,965
7,294
28,671
*
(2)
Clinics sold or closed (3)
421
4,521
(4,100
)
*
(2)
Net patient revenue from physical therapy operations
383,104
344,444
38,660
11.2
%
Other revenue
2,479
2,523
(44
)
(1.7
)%
Physical therapy operations
385,583
346,967
38,616
11.1
%
Industrial injury prevention services
58,082
58,660
(578
)
(1.0
)%
Management contracts
6,336
6,335
1
0.0
%
$
450,001
$
411,962
$
38,039
9.2
%
___________________________
(1)
See Glossary of Terms - Revenue Metrics for the definition.
(2)
Not meaningful.
(3)
Revenue from closed clinics includes revenue from the eight and 16 clinics closed or sold during the nine months ended September 30, 2023 and the year ended December 31, 2022, respectively.
Revenue from physical therapy operations increased $38.6 million 11.1% , to $385.6 million $347.0 million 12.2% to 3,737,584 for the 2023 Nine Months from 3,331,143 for the 2022 Nine Months, with patient visits at our mature clinics up 3.2% over the same periods.
Net rate per patient visit decreased to $102.50 $103.40
Revenue from IIP services decreased slightly to $58.1 million $58.7 million
Operating costs were $359.0 million 79.8% of net revenue, compared to $327.8 million 79.6% of net revenue, for the 2022 Nine Months. Salaries and related costs were 58.4% of net revenue for the 2023 Nine Months versus 57.5% for the 2022 Nine Months. Rent, supplies, contract labor and other costs as a percentage of total revenue were 20.4% for the 2023 Nine Months versus 21.0% for the 2022 Nine Months. The provision for credit losses as a percentage of total revenue was 1.0% in both the 2023 Nine Months and the 2022 Nine Months. On a cost per patient visit basis, physical therapy salaries and related costs per visit were $59.01 0.6% from $59.34 $82.35 0.9% from $83.09
Nine Months Ended September 30,
Variance
2023
2022
$
%
Operating costs related to:
(In thousands, except percentages)
Mature Clinics (1)
$
273,031
$
266,324
$
6,707
2.5
%
2023 Clinic additions
5,701
-
5,701
*
(2)
2022 Clinic additions
28,175
6,597
21,578
*
(2)
Clinics sold or closed (3)
880
3,877
(2,997
)
*
(2)
Physical therapy operations
307,787
276,798
30,989
11.2
%
Industrial injury prevention services
45,904
45,980
(76
)
(0.2
)%
Management contracts
5,317
4,991
326
6.5
%
$
359,008
$
327,769
$
31,239
9.5
%
___________________________
(1)
See Glossary of Terms - Revenue Metrics for the definition.
(2)
Not meaningful.
(3)
Operating costs from closed clinics include costs from the eight and 16 clinics closed or sold during the nine months ended September 30, 2023, and the year ended December 31, 2022, respectively.
Physical therapy operating costs increased $31.0 million 11.2% , to $307.8 million $276.8 million 3.2% increase in patient visits at mature clinics.
Operating costs from IIP services decreased slightly to $45.9 million $46.0 million
Gross profit increased $6.8 million 8.1% , to $91.0 million $84.2 million 20.2% in the 2023 Nine Months from 20.4% in the 2022 Nine Months. The following table provides a detailed breakdown of gross profit and related gross profit margins.
Nine Months Ended September 30,
2023
2022
Variance
$
Margin %
$
Margin %
$
%
(In thousands, except percentages)
Physical therapy operations
$
77,796
20.2
%
$
70,169
20.2
%
$
7,627
10.9
%
Industrial injury prevention services
12,178
21.0
%
12,680
21.6
%
(502
)
(4.0
)%
Management contracts
1,019
16.1
%
1,344
21.2
%
(325
)
(24.2
)%
Gross profit
$
90,993
20.2
%
$
84,193
20.4
%
$
6,800
8.1
%
Corporate office costs were $38.1 million 8.5% of net revenue, for the 2023 Nine Months compared to $34.2 million 8.3% of net revenue, for the 2022 Nine Months. The increase of $3.9 million 11.3% , in corporate office costs was primarily due to higher salaries related to merit increases, staff additions to support a larger number of clinics and inflationary and related impacts.
Operating income increased 5.9% , to $52.9 million 11.8% of net revenues, for the 2023 Nine Months from $50.0 million 12.1% of net revenues, in the 2022 Nine Months.
Total other (expense) income, net, was ($3.7) million during the 2023 Nine Months compared to $1.0 million
Interest expense, net of $2.3 million “Balance Sheet and Cash Flow” section below, was $7.3 million $3.5 million 5.1% for the 2023 Nine Months, with an all-in interest rate, including all associated costs, of 5.7% .
Interest income from investing excess cash (proceeds from the secondary offering sale of the Company’s stock completed in May 2023) in a high-yield savings account was $2.2 million
The Company revalued the contingent earn-out consideration related to acquisitions and recognized $0.2 million $2.0 million
The revaluation of a put-right liability resulted in $0.3 million $0.8 million
During the 2023 Nine Months, the Company recognized $0.5 million
The provision for income taxes was $10.8 million $11.0 million 28.1% for the 2023 Nine Months and 27.0% for the 2022 Nine Months. A computation of our effective income tax rate is as follows:
Nine Months Ended September 30,
2023
2022
(In thousands, except percentages)
Income before taxes
$
49,270
$
51,011
Less: net income attributable to non-controlling interest:
Redeemable non-controlling interest - temporary equity
(7,616
)
(7,220
)
Non-controlling interest - permanent equity
(3,314
)
(3,288
)
(10,930
)
(10,508
)
Income before taxes less net income attributable to non-controlling interest
38,340
40,503
Provision for income taxes
$
10,757
$
10,952
Percentage
28.1
%
27.0
%
Net income attributable to non-controlling interest (temporary and permanent) was $10.9 million $10.5 million
Adjusted EBITDA, a non-GAAP measure, was $58.7 million $2.9 million $55.8 million
Operating Results, a non-GAAP measure, was $27.4 million $1.97 $27.5 million $2.12
See pages 15 and 16 of this release for the definition and reconciliation of Adjusted EBITDA and Operating Results to the most directly comparable GAAP measure.
BALANCE SHEET AND CASH FLOW
Total cash and cash equivalents were $147.7 million $31.6 million $145.3 million $175.0 million $179.1 million $144.0 million
On May 30, 2023, the Company completed a secondary offering of its common stock resulting in net proceeds of $163.6 million $35.0 million $2.1 million
During the 2023 Nine Months, $55.1 million $36.6 million $97.5 million $23.0 million $8.1 million $7.1 million $163.6 million $33.8 million $17.7 million $11.8 million
The Company entered into an interest rate swap effective on June 30, 2022, which will mature on June 30, 2027. It has a $150.0 million $7.7 million $5.4 million $2.3 million 4.9% .
RECENT ACQUISITIONS
On July 31, 2023, the Company acquired a 70% equity interest in a five-clinic practice for a purchase price of $2.1 million 30% equity interest. The business currently generates approximately $2.4 million
On September 29, 2023, the Company acquired 70% equity interests in two practices with the current practice owners retaining 30% equity interests for a combined purchase price of $13.9 million $7.2 million
On October 31, 2023, the Company, through one of its IIP subsidiaries, acquired an IIP services and ergonomics software business for approximately $4.0 million 55% of the ergonomics software business. The businesses currently generate approximately $2.6 million
The Company’s strategy is to continue acquiring outpatient physical therapy practices, develop outpatient physical therapy clinics as satellites in existing partnerships, and continue acquiring companies that provide or serve the Company’s industrial injury prevention services.
QUARTERLY DIVIDEND
On November 6, 2023, the Company’s Board of Directors declared a quarterly dividend of $0.43
2023 EARNINGS GUIDANCE
Management currently expects the Company’s Adjusted EBITDA for 2023 to be within its previously provided guidance range of $75.0 million $80.0 million
CONFERENCE CALL INFORMATION
U.S. Physical Therapy’s management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on November 8, 2023 to discuss the Company’s financial results for the three and nine months ended September 30, 2023. Interested parties may participate in the call by dialing (800) 274-8461 (Primary) or (203) 518-9814 (Alternate) and conference ID of USPHQ323. Please call in approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company’s website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until February 6, 2024 at the Company’s website.
FORWARD LOOKING STATEMENTS
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
one of our acquisition agreements contains a put right related to a future purchase of a majority interest in a separate company;
the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
changes as the result of government enacted national healthcare reform;
business and regulatory conditions including federal and state regulations;
governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
revenue and earnings expectations;
some of our acquisition agreements contain contingent consideration, the value of which may impact future financial results;
legal actions, which could subject us to increased operating costs and uninsured liabilities;
general economic conditions, including but not limited to inflationary and recessionary periods;
actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S. or international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations;
our business depends on hiring, training, and retaining qualified employees
availability and cost of qualified physical therapists;
competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
acquisitions, and the successful integration of the operations of the acquired businesses;
impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
maintaining adequate internal controls;
maintaining necessary insurance coverage;
availability, terms, and use of capital; and
weather and other seasonal factors.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
GLOSSARY OF TERMS – REVENUE METRICS
Mature clinics
Net rate per patient visit
Patient visits
Average visits per day per clinic
ABOUT U.S. PHYSICAL THERAPY, INC.
Founded in 1990, U.S. Physical Therapy, Inc. currently operates 675 outpatient physical therapy clinics in 42 states. The Company’s clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 42 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com . The information included on that website is not incorporated into this press release.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Three Months Ended
Nine Months Ended
September 30,
September 30,
September 30,
September 30,
Net patient revenue
$
127,243
$
116,710
$
383,104
$
344,444
Other revenue
22,764
22,892
66,897
67,518
Net revenue
150,007
139,602
450,001
411,962
Operating cost:
Salaries and related costs
89,846
81,786
262,757
236,874
Rent, supplies, contract labor and other
30,707
29,696
91,651
86,703
Provision for credit losses
1,525
1,336
4,600
4,192
Total operating cost
122,078
112,818
359,008
327,769
Gross profit
27,929
26,784
90,993
84,193
Corporate office costs
12,048
11,889
38,052
34,186
Operating income
15,881
14,895
52,941
50,007
Other (expense) income
Interest expense, debt and other
(2,101
)
(2,013
)
(7,293
)
(3,540
)
Interest income
1,673
-
2,191
-
Change in fair value of contingent earn-out consideration
187
2,000
197
2,000
Change in revaluation of put-right liability
(145
)
785
(344
)
771
Equity in earnings of unconsolidated affiliate
206
304
806
983
Relief Funds
-
-
467
-
Other
78
65
305
790
Total other (expense) income
(102
)
1,141
(3,671
)
1,004
Income before taxes
15,779
16,036
49,270
51,011
Provision for income taxes
3,557
3,215
10,757
10,952
Net income
12,222
12,821
38,513
40,059
Less: Net income attributable to non-controlling interest:
Redeemable non-controlling interest - temporary equity
(1,976
)
(2,037
)
(7,616
)
(7,220
)
Non-controlling interest - permanent equity
(992
)
(1,227
)
(3,314
)
(3,288
)
(2,968
)
(3,264
)
(10,930
)
(10,508
)
Net income attributable to USPH shareholders
$
9,254
$
9,557
$
27,583
$
29,551
Basic and diluted earnings per share attributable to USPH shareholders (1)
$
0.51
$
0.72
$
1.72
$
2.27
Shares used in computation - basic and diluted
14,987
13,001
13,918
12,979
Dividends declared per common share
$
0.43
$
0.41
$
1.29
$
1.23
(1) See page 16 of this press release for the calculation of basic and diluted earnings per share.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS)
Three Months Ended
Nine Months Ended
September 30,
September 30,
September 30,
September 30,
Net income
$
12,222
$
12,821
$
38,513
$
40,059
Other comprehensive loss
Unrealized gain on cash flow hedge
1,276
6,473
2,340
5,942
Tax effect at statutory rate (federal and state)
(326
)
(1,654
)
(598
)
(1,518
)
Comprehensive income
$
13,172
$
17,640
$
40,255
$
44,483
Comprehensive income attributable to non-controlling interest
(2,968
)
(3,264
)
(10,930
)
(10,508
)
Comprehensive income attributable to USPH shareholders
$
10,204
$
14,376
$
29,325
$
33,975
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
September 30,
December 31,
ASSETS
(unaudited)
Current assets:
Cash and cash equivalents
$
147,685
$
31,594
Patient accounts receivable, less allowance for credit losses of $2,847 $2,829
52,958
51,934
Accounts receivable - other
18,469
16,671
Other current assets
9,387
11,067
Total current assets
228,499
111,266
Fixed assets:
Furniture and equipment
64,507
62,074
Leasehold improvements
46,212
42,877
Fixed assets, gross
110,719
104,951
Less accumulated depreciation and amortization
84,651
80,203
Fixed assets, net
26,068
24,748
Operating lease right-of-use assets
102,665
103,004
Investment in unconsolidated affiliate
12,256
12,131
Goodwill
522,907
494,101
Other identifiable intangible assets, net
112,112
108,755
Other assets
5,679
4,149
Total assets
$
1,010,186
$
858,154
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST
Current liabilities:
Accounts payable - trade
$
4,509
$
3,300
Accounts payable - due to seller of acquired business
-
3,204
Accrued expenses
35,846
37,413
Current portion of operating lease liabilities
34,446
33,709
Current portion of term loan and notes payable
7,555
7,863
Total current liabilities
82,356
85,489
Notes payable, net of current portion
2,037
1,913
Revolving facility
-
31,000
Term loan, net of current portion and deferred financing costs
139,459
142,918
Deferred taxes
26,487
21,303
Operating lease liabilities, net of current portion
76,884
77,934
Other long-term liabilities
14,758
13,029
Total liabilities
341,981
373,586
Redeemable non-controlling interest - temporary equity
174,697
167,515
Commitments and Contingencies
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding
-
-
Common stock, $.01 par value, 20,000,000 shares authorized, 17,202,053 and 15,216,326 shares issued,
respectively
172
152
Additional paid-in capital
279,124
110,317
Accumulated other comprehensive gain
5,746
4,004
Retained earnings
238,557
232,948
Treasury stock at cost, 2,214,737 shares
(31,628
)
(31,628
)
Total USPH shareholders’ equity
491,971
315,793
Non-controlling interest - permanent equity
1,537
1,260
Total USPH shareholders' equity and non-controlling interest - permanent equity
493,508
317,053
Total liabilities, redeemable non-controlling interest,
USPH shareholders' equity and non-controlling interest - permanent equity
$
1,010,186
$
858,154
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Nine Months Ended
September 30,
September 30,
OPERATING ACTIVITIES
Net income including non-controlling interest
$
38,513
$
40,059
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:
Depreciation and amortization
11,582
10,950
Provision for credit losses
4,600
4,192
Equity-based awards compensation expense
5,451
5,462
Change in deferred income taxes
5,393
6,077
Change in revaluation of put-right liability
344
(771
)
Change in fair value of contingent earn-out consideration
(197
)
(2,000
)
Equity of earnings in unconsolidated affiliate
(806
)
(983
)
Gain on sale of clinics and fixed assets
(106
)
(643
)
Changes in operating assets and liabilities:
Increase in patient accounts receivable
(5,415
)
(7,585
)
Increase in accounts receivable - other
(1,631
)
(4,551
)
Increase (decrease) in other current and long term assets
2,489
(4,273
)
Decrease in accounts payable and accrued expenses
(5,609
)
(4,568
)
Increase (decrease) in other long-term liabilities
535
(128
)
Net cash provided by operating activities
55,143
41,238
INVESTING ACTIVITIES
Purchase of fixed assets
(7,074
)
(7,290
)
Purchase of majority interest in businesses, net of cash acquired
(22,994
)
(18,573
)
Purchase of redeemable non-controlling interest, temporary equity
(7,804
)
(14,096
)
Purchase of non-controlling interest-permanent equity
(262
)
(280
)
Proceeds on sale of partnership interest, clinics, and fixed assets
7
740
Proceeds on sale of non-controlling interest, permanent equity
30
Proceeds on sale of partnership interest - redeemable non-controlling interest, temporary equity
815
401
Distributions from unconsolidated affiliate
681
1,220
Net cash used in investing activities
(36,601
)
(37,878
)
FINANCING ACTIVITIES
Distributions to non-controlling interest, permanent and temporary equity
(11,777
)
(11,760
)
Cash dividends paid to shareholders
(17,683
)
(15,990
)
Proceeds from revolving facility
24,000
61,000
Proceeds from term loan
-
150,000
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs
163,646
-
Payments on revolving facility
(55,000
)
(175,000
)
Principal payments on notes payable
(2,874
)
(496
)
Payments on term loan
(2,813
)
(1,779
)
Other
50
12
Net cash provided by financing activities
97,549
5,987
Net decrease in cash and cash equivalents
116,091
9,347
Cash and cash equivalents - beginning of period
31,594
28,567
Cash and cash equivalents - end of period
$
147,685
$
37,914
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for:
Income taxes
$
2,731
$
7,529
Interest paid
6,992
2,159
Non-cash investing and financing transactions during the period:
Purchase of businesses - seller financing portion
1,860
824
Notes payable related to purchase of redeemable non-controlling interest, temporary equity
1,017
1,074
Notes receivable related to sale of redeemable non-controlling interest, temporary equity
3,064
1,580
Notes payable related to the purchase of non-controlling interest, permanent equity
200
576
Notes receivable related to the sale of non-controlling interest, permanent equity
$
397
$
-
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA AND OPERATING RESULTS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. Management believes providing Adjusted EBITDA and Operating Results to investors is useful information for comparing the Company's period-to-period results.
Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, Relief Funds, changes in revaluation of put-right liability, equity-based awards compensation expense, and related portions for non-controlling interests.
Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less changes in revaluation of put-right liability, Relief Funds, changes in fair value of contingent earn-out consideration, and any allocations to non-controlling interests, all net of taxes. Operating Results per share also exclude the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.
Management uses Adjusted EBITDA and Operating Results, which eliminates certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.Management believes that Adjusted EBITDA and Operating Results are useful measures for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.
Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
Three Months Ended
Nine Months Ended
September 30,
September 30,
September 30,
September 30,
(In thousands, except per share data)
Adjusted EBITDA
Net income attributable to USPH shareholders
$
9,254
$
9,557
$
27,583
$
29,551
Adjustments:
Provision for income taxes
3,557
3,215
10,757
10,953
Depreciation and amortization
3,966
3,652
11,582
10,950
Interest expense, debt and other
2,101
2,013
7,293
3,540
Equity-based awards compensation expense
1,859
1,802
5,451
5,462
Change in revaluation of put-right liability
145
(785
)
344
(771
)
Change in fair value of contingent earn-out consideration
(187
)
(2,000
)
(197
)
(2,000
)
Interest income
(1,673
)
-
(2,191
)
-
Other (income) expense
(78
)
(65
)
(305
)
(790
)
Relief Funds
-
-
(467
)
-
Allocation to non-controlling interests
(358
)
(402
)
(1,119
)
(1,098
)
Adjusted EBITDA (a non-GAAP measure)
$
18,586
$
16,987
$
58,731
$
55,797
Operating Results
Net income attributable to USPH shareholders
$
9,254
$
9,557
$
27,583
$
29,551
Adjustments:
Change in fair value of contingent earn-out consideration
(187
)
(2,000
)
(197
)
(2,000
)
Change in revaluation of put-right liability
145
(785
)
344
(771
)
Relief Funds
-
-
(467
)
-
Allocation to non-controlling interest
-
33
Tax effect at statutory rate (federal and state)
11
711
73
708
Operating Results (a non-GAAP measure)
$
9,223
$
7,483
$
27,369
$
27,488
Operating Results per share (a non-GAAP measure)
$
0.62
$
0.58
$
1.97
$
2.12
Earnings per share
Computation of earnings per share - USPH shareholders:
Net income attributable to USPH shareholders
$
9,254
$
9,557
$
27,583
$
29,551
Charges to retained earnings:
Revaluation of redeemable non-controlling interest
(2,242
)
(196
)
(4,988
)
(193
)
Tax effect at statutory rate (federal and state)
573
50
1,274
49
$
7,585
$
9,411
$
23,869
$
29,407
Earnings per share (basic and diluted)
$
0.51
$
0.72
$
1.72
$
2.27
Shares used in computation - basic and diluted
14,987
13,001
13,918
12,979
* Revised to conform to current year presentation.
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
REVENUE METRICS
Number of Clinics
Net Rate Per Patient
(1)
Patient Visits (1)
Average Visits Per Day
(1)
2023
2022
2023
2022
2023
2022
2023
2022
First quarter
647
601
$103.12
$103.00
1,227,490
1,063,519
29.8
27.9
Second quarter
656
608
$102.03
$103.18
1,267,140
1,145,554
30.4
29.5
Third quarter
672
614
$102.37
$104.01
1,242,954
1,122,070
29.7
28.8
Fourth quarter
640
$104.28
1,152,139
29.1
(1) See definition of the metrics above in the Glossary of Terms – Revenue Metrics on page 9.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231107405544/en/
U.S. Physical Therapy, Inc.
chendrickson@usph.com
Source: U.S. Physical Therapy, Inc.
What was USPH's net patient revenue from physical therapy operations in the 2023 Third Quarter?
The net patient revenue from physical therapy operations increased by 9.0% to $127.2 million for the 2023 Third Quarter from $116.7 million for the 2022 Third Quarter.
What was the percentage increase in adjusted EBITDA for USPH?
Adjusted EBITDA increased by $1.6 million to $18.6 million for the 2023 Third Quarter from $17.0 million for the 2022 Third Quarter.
What was the change in net income attributable to USPH's shareholders for the 2023 Third Quarter?
Net income attributable to USPH’s shareholders decreased to $9.3 million for the 2023 Third Quarter compared to $9.6 million for the 2022 Third Quarter.
